Fact CheckerSign in

NCT07405788Active, not recruiting

Percutaneous Coronary Intervention for Myocardial Infarction at Fujian Provincial Hospital

A Registration Study on Percutaneous Coronary Intervention for Patients With Myocardial Infarction at Fujian Provincial Hospital

Source: ClinicalTrials.gov · Last updated 12 Feb 2026

Brief summary (registry, in English)

Research Objectives: This clinical trial aims to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) in patients with myocardial infarction (MI). The primary objective is to determine whether this approach can reduce the incidence of major adverse cardiovascular events (MACE) compared to current conservative treatment. Research Questions: This study aims to address the following key questions: Does standard PCI improve the clinical outcomes of MI patients (such as cardiovascular death, recurrent myocardial infarction, or revascularization due to ischemia-driven vascular reconstruction)? How safe is PCI, especially in terms of bleeding risk, surgical-related complications, or other adverse events? Does PCI have a significant impact on specific secondary endpoints (such as stent thrombosis, hospitalization for heart failure, or quality of life indicators)?

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
1344 (actual)
First submitted
29 Dec 2025
Start date
1 Jan 2017
Primary completion date
31 Dec 2027
Lead sponsor
Kaiyang Lin
NCT number
NCT07405788

What you commit to

  • Study type: Interventional
  • Participants enrolled: 1344
  • From 1 Jan 2017 to the primary completion date, 31 Dec 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Inclusion Criteria:
    • Clinical diagnosis of acute myocardial infarction.
    • Successful direct or emergency PCI of the infarct-related artery.
    • Ability to undergo randomization post-PCI.
    • Ability to understand and voluntarily sign the informed consent form.
  • Exclusion Criteria:
    • PCI failure (final TIMI flow \< grade 2) or presence of untreated severe stenosis.
    • Planned staged PCI or other cardiac surgery within 3 months.
    • Cardiogenic shock (Killip class IV), severe structural heart disease, or contraindications to PCI trial intervention.
    • Active bleeding or high bleeding risk.
    • Known allergy to the trial drug or its components.
    • ALT/AST \> 3x upper limit of normal (ULN); eGFR \< 30 mL/min/1.73 m².
    • Non-cardiovascular disease with life expectancy \< 1 year (e.g., active malignancy).
    • History of hemorrhagic stroke, or any ischemic stroke/transient ischemic attack within the past 6 months.
    • Requirement for long-term oral anticoagulation therapy.
    • Pregnancy, lactation, or women of childbearing potential not using effective contraception.
    • Current participation in another interventional clinical trial.
    • Any condition that may affect trial compliance, safety assessment, or result interpretation per investigator judgment.

Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.